Schizophrenia Research
Volume 123, Issue 2 , Pages 276-277 , November 2010

A head-to-head comparison of sertindole and risperidone on metabolic parameters

  • Marc De Hert

      Affiliations

    • University Psychiatric Center Catholic University Leuven, Leuvensesteenweg 517, 3070 Kortenberg, Belgium
    • Corresponding Author InformationCorresponding author. UPC KUL campus Kortenberg, Leuvensesteenweg 517, 3070 Kortenberg, Belgium. Tel.: +32 2 758 05 11; fax: +32 2 759 98 78.
    • ,
  • Aurélia Mittoux

      Affiliations

    • H. Lundbeck A/S, Ottiliavej 9, Valby, Copenhagen, Denmark
    • ,
  • Yuan He

      Affiliations

    • H. Lundbeck A/S, Ottiliavej 9, Valby, Copenhagen, Denmark
    • ,
  • Joseph Peuskens

      Affiliations

    • University Psychiatric Center Catholic University Leuven, Leuvensesteenweg 517, 3070 Kortenberg, Belgium

Received 29 March 2010 ,Revised 19 July 2010 ,Accepted 27 July 2010.

References 

  1. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome — a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet. Med. 2006;23:469–480
  2. De Hert M, Dekker JM, Wood D, Kahl KG, Möller HJ. Cardiovascular disease and diabetes in people with severe mental illness. Position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur. Psychiatry. 2009;24(6):412–424
  3. De Hert M, Schreurs V, Vancampfort D, van Winkel R. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry. 2009;8(1):15–22
  4. Fleischhacker WW, Cetkovich-Bakmas M, De Hert M, Hennekens CH, Lambert M, Leucht S, et al. Cormorbid somatic illnesses in patients with severe mental disorders: clinical, policy and research challenges. J. Clin. Psychiatry. 2008;69:514–519
  5. Leucht S, Burkard T, Henderson J, Maj M, Sartorius N. Physical illness and schizophrenia: a review of the literature. Acta Psychiatr. Scand. 2007;116:317–333
  6. Peuskens J, Moore N, Azorin JM, Toumi M, Cochran J. The European sertindole safety and exposure survey: a follow-up study of 8600 patients. Pharmacoepidemiol. Drug Saf. 2007;16(7):804–811
  7. Peuskens J, Tanghøj P, Mittoux A, Cohort Sertindole. The Sertindole Cohort Prospective (SCoP) study: rationale, design and methodology. Pharmacoepidemiol. Drug Saf. 2008;17(5):425–433
  8. Saha S, Chant D, Mcgrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?. Arch. Gen. Psychiatry. 2007;64:1123–1131
  9. Thomas SHL, Drici MD, Hall GC, Crocq MA, Everitt B, Lader MH, et al. Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP). Acta Psychiatry Scand. 2010;1–11:
  10. Weinmann S, Read J, Aderhold V. Influence of antipsychotics on mortality in schizophrenia: systematic review. Schizophr. Res. 2009;113(1):1–11

☆ Clinical trial registration: Safety study of sertindole versus risperidone under normal conditions of use. NCT 00856583 (EudraCT 2004-000213-19). http://clinicaltrials.gov/ct2/results?term=00856583.

PII: S0920-9964(10)01446-5

doi: 10.1016/j.schres.2010.07.030

Schizophrenia Research
Volume 123, Issue 2 , Pages 276-277 , November 2010

Article Tools

* Image Usage & Resolution